A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Registration Number
- NCT00244244
- Lead Sponsor
- CytRx
- Brief Summary
The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.
- Detailed Description
Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase (SOD1) transgenic mouse model of ALS. Furthermore, it has been demonstrated to have neuroprotective and neuroregenerative effects in other rat models of nerve damage. Molecular chaperone proteins are critical in the cellular response to stress and protein misfolding. Recent data suggest that the SOD1 mutation responsible for ALS in some patients with familial disease reduces the availability of a variety of molecular chaperones, and thus weakens their ability to respond to cellular stress. Protein misfolding and consequent aggregation may play a role in the pathogenesis of both the familial and sporadic forms of ALS. Therapeutic agents such as arimoclomol that improve cellular chaperone response to protein misfolding may be helpful in ALS.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
- Familial or sporadic ALS
- Vital capacity equal to or more than 60% predicted value for gender, height and age at the screening visit
- First ALS symptoms occurred no more than five years prior to screening
- Must be able to take oral medication
- Dependence on mechanical ventilation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Pharmacokinetics ALSFRS-R Vital Capacity
Trial Locations
- Locations (10)
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Penn State Milton S. Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
University of Miami School of Medicine
🇺🇸Miami, Florida, United States
Hennepin Faculty Associates/Berman Center
🇺🇸Minneapolis, Minnesota, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Duke University
🇺🇸Durham, North Carolina, United States
Drexel University College of Medicine
🇺🇸Philadelphia, Pennsylvania, United States
University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
University of California, Irvine Medical Center
🇺🇸Irvine, California, United States
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States